MOTS-c: what an exercise signal can—and cannot—tell us about treatment

The appeal of MOTS-c is easy to understand. If a molecule participates in the body’s response to exercise, perhaps it could become a treatment for people whose metabolism or physical function is impaired. The scientific question is worthwhile. The evidence must still show whether administering that molecule produces a useful effect in people. [1] [2]

There has been commercial interest as well. CohBar tested CB4211, a modified relative of MOTS-c, in an early human trial and announced initial findings in 2021. A separate, newer registry entry describes a proposed study using MOTS-c itself. Those are distinct programs, with distinct evidence: an analog’s reported results do not validate a native-peptide product, and a registered plan does not establish a treatment effect. [5] [6] [7]

A message from the cell’s energy system

Mitochondria help cells convert nutrients into usable energy. They also carry a small amount of DNA of their own, separate from the DNA in the cell nucleus. Researchers identified a stretch of mitochondrial DNA containing the instructions for MOTS-c, a peptide made from 16 amino acids—the building blocks of proteins. The 2015 discovery study linked it to metabolic regulation in cells and mice. [1]

One pathway involved is AMPK, a protein that helps cells respond to their energy state. In laboratory work, MOTS-c altered metabolic processes in ways that activated this energy-sensing pathway. In mice, treatment affected insulin sensitivity—the ability of tissues to respond to insulin—and responses to a high-fat diet. This gives researchers a plausible mechanism to investigate. It does not yet tell us that the same intervention has a favorable balance of benefits and harms in patients. [1]

Core concept: measuring a signal is different from testing a treatment

MOTS-c made by the body is called endogenous MOTS-c. Measuring it during exercise tells researchers how the body responds.

Administered MOTS-c is a preparation given from outside the body. The original, unmodified peptide is also called native MOTS-c. Its effects depend on the exact preparation, how much reaches the tissues and for how long, and the person receiving it.

An analog, such as CB4211, is a deliberately modified related molecule. Modification can be useful in drug development, but the resulting candidate needs its own evidence. [1] [7]

A rise in the body’s own peptide does not show that an injection will reproduce exercise. Nor does it establish a blood concentration that people should try to reach.

The same distinction applies beyond MOTS-c. A biological change can accompany a beneficial activity without being responsible for all its benefits. Even if that change contributes, reproducing it alone may produce a different result.

What the human exercise studies found

The widely cited Reynolds study in 2021 followed ten healthy, sedentary young men exercising on a stationary bicycle. Their own MOTS-c increased in muscle and blood during or after exercise. Four hours later, the muscle signal remained elevated while circulating levels had returned to baseline. The participants had exercised; they had not received MOTS-c. [2]

That difference between muscle and blood is useful. It shows why the location and timing of a measurement matter. A blood sample taken soon after exercise may tell a different story from a muscle sample collected hours later. Neither alone is a complete measure of the training response.

Later studies add detail rather than a single, uniform answer:

Frame running uses a supported running frame. The study is also a reminder to look at who participated. Adults with cerebral palsy had prior experience using a running frame and could exercise continuously for 45 minutes. Some follow-up samples were unavailable. The findings therefore cannot be assumed to describe every person with cerebral palsy, every activity level, or every exercise session. [4]

The knee-extension paper separately treated genetically modified mice with MOTS-c. Those mouse experiments should not be confused with its human exercise measurements. The humans were not a treatment-efficacy trial. [12]

Taken together, these studies support a role for MOTS-c in exercise physiology while leaving important questions open. Exercise mode, participants, sampling time, the part of the body sampled, and measurement methods differ. The findings do not establish a MOTS-c target for judging whether someone’s workout was effective.

What changes when researchers give MOTS-c to mice?

An intervention experiment can ask a more direct question than a measurement study: does giving the compound change an outcome compared with a control? The discovery research reported favorable effects on insulin resistance and diet-induced obesity in mice. Later work reported improvements in treadmill performance and selected measures of late-life physical function. [1] [2]

These are reasons to continue research. They also need to keep their actual outcome labels. A mouse running farther on a treadmill has shown a performance change in that experiment. It has not established prevention of disability in people. Improved glucose handling is a metabolic finding; it is not yet evidence that a human treatment prevents heart attacks or extends life.

The lifespan result is especially easy to overstate. In the Reynolds study, the overall survival comparison was not statistically significant: p = 0.23. Some late-life functional tests improved, but the whole survival curve did not establish a lifespan benefit. This leaves a benefit unconfirmed; it does not prove that the treatment had no effect. The study’s authors described a favorable trend and the need for larger cohorts. Two authors also disclosed consulting and shareholding in CohBar. [2]

This is why “healthspan” deserves an explanation whenever it appears in a headline. In an animal experiment, it usually refers to the particular functional or health measurements collected. Readers need to know which ones improved, which did not, and whether survival was assessed separately.

Human drug development: two different evidence tracks

The two programs ask different questions and concern different molecules:

Hudson Biotech is the sponsor named in MOTS-MET. The plan is to measure how insulin sensitivity changes over 12 weeks using a test in which participants drink a glucose solution, and to record health problems over 16 weeks. These are useful treatment and safety questions, but the entry gives no results. Planned completion dates and a recruitment label do not show how treatment turned out. [5]

The benefits and risks of giving native MOTS-c to people remain unclear. Measurements made during exercise and treatment experiments in mice cannot establish a useful human treatment, and the MOTS-MET entry supplies no treatment results.

CB4211 has a different kind of information. CohBar’s August 2021 announcement described a four-week fatty-liver cohort with 11 treated participants and nine receiving placebo. Safety and how well participants tolerated the drug were the main objectives. Changes in liver enzymes, blood glucose, weight, and liver fat were exploratory measures intended to look for early signs of benefit. The company reported favorable changes in selected liver-enzyme and glucose measures. Weight reduction was described as a trend, while liver fat fell in both groups. [7]

CohBar reported no serious adverse events. In the four-week cohort, injection-site reactions were the only adverse events reported in more than 10% of treated participants; they were described as temporary and generally mild to moderate. Participants stayed in the study unit during treatment. These small, short-term, sponsor-reported findings do not establish lasting benefit, long-term safety, or effectiveness of native MOTS-c. [7]

“No results posted in the registry” therefore does not mean no data have ever been announced. Equally, an initial company announcement is not a complete peer-reviewed efficacy report. Keeping the two documents separate gives a more accurate account of what is known.

What would establish a useful treatment?

An exercise-substitution claim would require direct evidence in people. A study would need to define which part of exercise’s benefit it aimed to reproduce, use an appropriate comparison, and measure a meaningful outcome over enough time to evaluate benefits and harms. A change in a signaling pathway or blood marker cannot answer all those questions.

For example, a future treatment might improve insulin sensitivity in a defined group with metabolic disease. That would be useful evidence for that application. It would still leave separate questions about strength, endurance, bone health, disability, and longevity. A result in people with a disease also cannot automatically predict what happens in healthy, active adults.

Drug development must also establish how a preparation behaves after administration: whether it reaches relevant tissue, how long exposure lasts, and what unwanted effects appear. These questions remain especially important when the rationale begins with a molecule the body already produces. Natural origin describes biology; it does not define the safety of an outside dose.

The safety and US regulatory questions

The US Food and Drug Administration (FDA) found insufficient clinical evidence in its 2026 assessment for the proposed uses of the native MOTS-c substances, including obesity and osteoporosis, a disease that weakens bones. It also identified major gaps in human exposure and safety information. The agency’s safety notice flags possible immune responses, peptide impurities, and uncertainty about the preparation’s exact properties. These are unresolved risks, not a measured adverse-event rate. [8] [9]

In the United States, FDA’s July 2026 advisory materials considered whether two forms of MOTS-c, the free base and acetate salt, could be used to prepare medicines in pharmacies. The advisory committee’s recommendations do not bind FDA. Considering an ingredient for pharmacy preparation does not mean a finished medicine has been approved or shown to be safe and effective for a particular use. [8] [10]

Product quality and clinical evidence must also be distinguished. A preparation can be described as pure without having been shown to improve a patient’s health. The exact molecule, manufacturing controls, appropriate exposure, clinical outcomes, and harms all need evidence of their own.

What a reader can use now

Physical activity’s benefits are supported by evidence across cardiovascular, metabolic, mental-health, and functional outcomes. WHO guidance includes people with chronic conditions and disabilities and emphasizes that some activity is better than none. Those benefits do not depend on proving that a single peptide explains them. [11]

For someone interested in MOTS-c research, the next useful development would be transparent human treatment results. The key questions are practical:

• Was the study measuring the body’s own MOTS-c, administering native MOTS-c, or testing an analog?

• Did the result concern a laboratory marker or an outcome that mattered to participants?

• What happened in the comparison group, and where was a benefit unproven or uncertain?

• Were the harms, follow-up, and full methods available, or only an initial company announcement?

MOTS-c may help explain how cellular energy signals interact with physical stress. Turning that insight into a treatment requires evidence that a defined intervention helps people. The current studies support investigation while leaving that clinical question open.